p.125 抽出テキスト

Circulation 2003; 108: 3084-3091. PMID: 14638546 858. ARVC Risk Calculator. https://arvcrisk.com/ 859. Cadrin-Tourigny J, Bosman LP, Nozza A, et al. A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 2022; 43: e1-e9. PMID: 35441664 860. Jordà P, Bosman LP, Gasperetti A, et al. Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator. Eur Heart J 2022; 43: 3041-3052. PMID: 35766180 861. Protonotarios A, Bariani R, Cappelletto C, et al. Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator. Eur Heart J 2022; 43: 3053-3067. PMID: 35766183 862. Carrick RT, Gasperetti A, Protonotarios A, et al. A novel tool for arrhythmic risk stratification in desmoplakin gene variant carriers. Eur Heart J 2024; 45: 2968-2979. PMID: 39011630 863. Nakagawa H, Ikeda A, Sharma T, et al. Comparison of In Vivo Tissue Temperature Profile and Lesion Geometry for Radiofrequency Ablation With High Power-Short Duration and Moderate Power-Moderate Duration: Effects of Thermal Latency and Contact Force on Lesion Formation. Circ Arrhythm Electrophysiol 2021; 14: e009899. PMID: 34138641 864. Elliott PM, Anastasakis A, Asimaki A, et al. Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report. Eur J Heart Fail 2019; 21: 955-964. PMID: 31210398 865. James CA, Bhonsale A, Tichnell C, et al. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol 2013; 62: 1290-1297. PMID: 23871885 866. Lie ØH, Dejgaard LA, Saberniak J, et al. Harmful Effects of Exercise Intensity and Exercise Duration in Patients With Arrhythmogenic Cardiomyopathy. JACC Clin Electrophysiol 2018; 4: 744-753. PMID: 29929667 867. Saberniak J, Hasselberg NE, Borgquist R, et al. Vigorous physical activity impairs myocardial function in patients with arrhythmogenic right ventricular cardiomyopathy and in mutation positive family members. Eur J Heart Fail 2014; 16: 1337-1344. PMID: 25319773 868. Gasperetti A, Targetti M, Olivotto I. Anti-arrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: The importance of optimal beta-blocker dose titration. Int J Cardiol 2021; 338: 150-151. PMID: 34139230 869. Marcus GM, Glidden DV, Polonsky B, et al. Multidisciplinary Study of Right Ventricular Dysplasia Investigators. Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. J Am Coll Cardiol 2009; 54: 609-615. PMID: 19660690 870. Ermakov S, Gerstenfeld EP, Svetlichnaya Y, et al. Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm 2017; 14: 564-569. PMID: 27939893 871. Daimee UA, Assis FR, Murray B, et al. Clinical outcomes of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy: Insights from the Johns Hopkins ARVC Program. Heart Rhythm 2021; 18: 1369-1376. PMID: 33933674 872. Gandjbakhch E, Laredo M, Berruezo A, et al. Outcomes after catheter ablation of ventricular tachycardia without implantable cardioverter-defibrillator in selected patients with arrhythmogenic right ventricular cardiomyopathy. Europace 2021; 23: 1428-1436. PMID: 34427302 873. 日本循環器学会,日本心不全学会.2025 年改訂版 心不全診療ガイドライン.https://www.j-circ.or.jp/cms/wp-content/uploads/2025/03/ JCS2025_Kato.pdf 874. Wlodarska EK, Wozniak O, Konka M, et al. Thromboembolic complications in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Europace 2006; 8: 596-600. PMID: 16760233 875. Toso E, De Lio F, Bocchino PP, et al. Risk of cardioembolic ischemic events and relation to atrial fibrillation/flutter in patients with arrhythmogenic cardiomyopathy during a long-term follow-up. Int J Cardiol 2023; 389: 131200. PMID: 37482095 876. Hofer S, Schlimp CJ, Casu S, et al. Management of Coagulopathy in Bleeding Patients. J Clin Med 2021; 11: 1. PMID: 35011742 877. Parks SB, Kushner JD, Nauman D, et al. Lamin A/C mutation analysis in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy. Am Heart J 2008; 156: 161-169. PMID: 18585512 878. Hasselberg NE, Haland TF, Saberniak J, et al. Lamin A/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation. Eur Heart J 2018; 39: 853-860. PMID: 29095976 879. Arbustini E, Pilotto A, Repetto A, et al. Autosomal dominant dilated cardiomyopathy with atrioventricular block: a lamin A/ C defect-related disease. J Am Coll Cardiol 2002; 39: 981-990. PMID: 11897440 880. van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol 2012; 59: 493-500. PMID: 22281253 881. Kumar S, Androulakis AF, Sellal JM, et al. Multicenter Experience With Catheter Ablation for Ventricular Tachycardia in Lamin A/C Cardiomyopathy. Circ Arrhythm Electrophysiol 2016; 9: e004357. PMID: 27506821 882. Tobita T, Nomura S, Fujita T, et al. Genetic basis of cardiomyopathy and the genotypes involved in prognosis and left ventricular reverse remodeling. Sci Rep 2018; 8: 1998. PMID: 29386531 883. Paldino A, Dal Ferro M, Stolfo D, et al. Prognostic Prediction of Genotype vs Phenotype in Genetic Cardiomyopathies. J Am Coll Cardiol 2022; 80: 1981-1994. PMID: 36396199 884. Nakajima K, Aiba T, Makiyama T, et al. Clinical Manifestations and Long-Term Mortality in Lamin A/C Mutation Carriers From a Japanese Multicenter Registry. Circ J 2018; 82: 2707-2714. PMID: 30078822 885. van Rijsingen IA, Bakker A, Azim D, et al. Lamin A/C mutation is independently associated with an increased risk of arterial and venous thromboembolic complications. Int J Cardiol 2013; 168: 472-477. PMID: 23073275 886. Brodt C, Siegfried JD, Hofmeyer M, et al. Temporal relationship of conduction system disease and ventricular dysfunction in LMNA cardiomyopathy. J Card Fail 2013; 19: 233-239. PMID: 23582089 887. Meune C, Van Berlo JH, Anselme F, et al. Primary prevention of sudden death in patients with lamin A/C gene mutations. N Engl J Med 2006; 354: 209-210. PMID: 16407522 888. van Berlo JH, de Voogt WG, van der Kooi AJ, et al. Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol Med (Berl) 2005; 83: 79-83. PMID: 15551023 889. McKeon FD, Kirschner MW, Caput D. Homologies in both primary and secondary structure between nuclear envelope and intermediate filament proteins. Nature 1986 ; 319: 463-468. PMID: 3453101 890. Fisher DZ, Chaudhary N, Blobel G. cDNA sequencing of nuclear lamins A and C reveals primary and secondary structural homology to intermediate filament proteins. Proc Natl Acad Sci U S A 1986; 83: 6450-6454. PMID: 3462705 891. Janin A, Gache V. Nesprins and Lamins in Health and Diseases of Cardiac and Skeletal Muscles. Front Physiol 2018; 9: 1277. PMID: 30245638 892. Bonne G, Di Barletta MR, Varnous S, et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet 1999; 21: 285-288. PMID: 10080180 893. Vigouroux C, Magré J, Vantyghem MC, et al. Lamin A/C gene: sex-determined expression of mutations in Dunnigan-type familial partial lipodystrophy and absence of coding mutations in congenital and acquired generalized lipoatrophy. Diabetes 2000; 49: 1958- 1962. PMID: 11078466 894. De Sandre-Giovannoli A, Chaouch M, Kozlov S, et al. Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope proteins, cause autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth disorder type 2) and mouse. Am J Hum Genet 2002; 70: 726-736. PMID: 11799477 895. Eriksson M, Brown WT, Gordon LB, et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 2003; 423: 293-298. PMID: 12714972 896. Worman HJ, Schirmer EC. Nuclear membrane diversity: underlying tissue-specific pathologies in disease? Curr Opin Cell Biol 2015; 34: 101-112. PMID: 26115475 897. Jakobs PM, Hanson EL, Crispell KA, et al. Novel lamin A/C mutations in two families with dilated cardiomyopathy and conduction system disease. J Card Fail 2001; 7: 249-256. PMID: 11561226 898. Holmström M, Kivistö S, Heliö T, et al. Late gadolinium enhanced cardiovascular magnetic resonance of lamin A/C gene mutation related dilated cardiomyopathy. J Cardiovasc Magn Reson 2011; 13: 30. PMID: 21689390 899. Narula N, Favalli V, Tarantino P, et al. Quantitative expression of the mutated lamin A/C gene in patients with cardiolaminopathy. J Am Coll Cardiol 2012; 60: 1916-1920. PMID: 23062543